The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option. In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use.
Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie.
For information on open clinical trials please refer to the Cancer Trials Ireland website here and also to basket trials here.
Sarcoma Chemotherapy Regimens
| Regimen Name |
Indication |
|
Dacarbazine (1.2 g/m2) Therapy –21 day
Regimen
|
00511a
Treatment of metastatic soft tissue sarcoma
|
|
DOXOrubicin 75mg/m2 Monotherapy
Regimen
|
00500a
Treatment of locally advanced unresectable or metastatic soft tissue sarcoma.
|
|
DOXOrubicin (25mg/m2/day and CISplatin (100mg/m2) Therapy-21 day cycle
Regimen
|
00420a
Neoadjuvant/Adjuvant therapy of osteosarcoma.
|
|
DOXOrubicin (60) and Ifosfamide Therapy
Regimen
|
00391a
Treatment of locally advanced unresectable or metastatic soft tissue sarcomas.
|
|
DOXOrubicin (75) and Ifosfamide Therapy
Regimen
|
00392a
Neoadjuvant treatment of high risk soft tissue sarcoma.
00392b
Treatment of locally advanced unresectable or metastatic soft tissue sarcomas.
|
|
Gemcitabine and DOCEtaxel Therapy* - 21 day
Regimen
|
00501a
Treatment of locally advanced unresectable or metastatic soft tissue sarcoma.
|
|
Imatinib Therapy-GIST
Regimen
|
00335a
Treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
00335b
Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.
|
|
(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy
Regimen
|
00463a
Neoadjuvant/Adjuvant therapy of localised or metastatic high grade osteosarcoma of an extremity/axial skeleton (excluding craniofacial sites) -all disease sites amenable to complete surgical resection
|
|
Mifamurtide
Regimen
|
00100a
Treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults.
|
|
PAZOPanib Therapy
Regimen
|
00445b
Treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
|
|
Pegylated Liposomal DOXOrubicin 20mg/m2 (CAELYX®) 21 days
Regimen
|
00462a
Treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts ( < 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.
|
|
Regorafenib Monotherapy
Regimen
|
00244b
Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.
|
|
SUNItinib 50mg Therapy
Regimen
|
00325a
Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.
|
|
Trabectedin Monotherapy
Regimen
|
00374a
Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.
|
|
vinBLAStine and Methotrexate Therapy
Regimen
|
00554a
Treatment of advanced aggressive fibromatosis
|
|
